Piper Sandler Maintains Neutral on Tvardi Therapeutics, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 61.3%

Neg 61.3% Neu 0% Pos 0%

Piper Sandler analyst Yasmeen Rahimi maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Neutral and lowers the price target from $4 to $3.